The use of monoclonal antibodies against TNF-α has shown mixed results, some proven successful in inducing remission in cases of IBD (248), but also at the cost of adverse events and high number of non-responders over time (249, 250). The gene discussed is TNF; the disease is irritable bowel syndrome.